Differences in coated-platelet production between frontotemporal dementia and alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 3, 2009, Pages 234-237

  Prodan, Calin I ^a,c   Ross, Elliott D ^a,c   Vincent, Andrea S ^b   Dale, George L ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Amyloid; Frontotemporal dementia; Platelets

Indexed keywords

AMYLOID PRECURSOR PROTEIN; COLLAGEN; THROMBIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COATED PLATELET; CONTROLLED STUDY; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPOIESIS;

AGED; ALZHEIMER DISEASE; BLOOD PLATELETS; FRONTOTEMPORAL DEMENTIA; HUMANS; PLATELET ACTIVATION;

EID: 70349158734     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318199dd1a     Document Type: Article

References (27)

1. Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen and convulxin. Blood. 2000;95:1694-1702.
2. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415:175-179.
3. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185-2192.
4. Prodan CI, Szasz R, Vincent AS, et al. Coated-platelets retain amyloid precursor protein on their surface. Platelets. 2006; 17:56-60.
5. Prodan CI, Ross ED, Vincent AS, et al. Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol. 2007;254:548-549.
6. Prodan CI, Ross ED, Vincent AS, et al. Coated-platelets are higher in amnestic versus non-amnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord. 2007;21: 259-261.
7. Prodan CI, Ross ED, Vincent AS, et al. Rate of progression in Alzheimer's longitudinal study. Translational Res. 2008;152:99-102.
8. Ross ED, Shah SN, Prodan CI, et al. Changing relative prevalence of Alzheimer disease versus non-Alzheimer disease dementias: have we underestimated the looming dementia epidemic? Dement Geriatr Cogn Disord. 2006;22:273-277.
9. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
10. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
11. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803-1809.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
14. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
15. Hodges JR. Frontotemporal dementia (Pick's disease): clinical features and assessment. Neurology. 2001;56:S6-S10.
16. Prodan CI, Joseph PM, Vincent AS, et al. Coated-platelet levels are in.uenced by smoking, aspirin and selective serotonin reuptake inhibitors. J Thromb Haemost. 2007;5: 2149-2151.
17. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006;129:2823-2839.
18. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5-22.
19. Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615-1621.
20. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
21. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry. 2006;77:714-718.
22. Kertesz A, Blair M, McMonagle P, et al. The diagnosis and course of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2007;21:155-163.
23. Varma AR, Snowden JS, Lloyd JJ, et al. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184-188.
24. Liscic RM, Storandt M, Cairns NJ, et al. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol. 2007;64:535-540.
25. Farlow MR, Cummings JL. Efective pharmacologic management of Alzheimer's disease. Am J Med. 2007;120:388-397.
26. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007;21:S79-S87.
27. Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15: 84-87.